A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants - Trial NCT06356259
Access comprehensive clinical trial information for NCT06356259 through Pure Global AI's free database. This Phase 1 trial is sponsored by ImmunoRx Pharma Inc. and is currently Recruiting. The study focuses on Healthy Participants. Target enrollment is 81 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
ImmunoRx Pharma Inc.
Timeline & Enrollment
Phase 1
Jun 07, 2023
Jan 22, 2025
Primary Outcome
Number of participants with Serious Adverse Events,Number of participants with Treatment-Emergent Adverse Events
Summary
The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics with
 intravenous(IV) administration of IRX-010 in Healthy Participants.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06356259
Non-Device Trial